Kazia Therapeutics Limited - ADR
$12.83
$0.20
(1.58%)
As on 02-Sep-2026 14:37EDT
Market cap
$155 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
5.8
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-7 Mln
-
ROE
-1.1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.7
-
Debt to Equity
-0
-
Book Value
$--
-
EPS
$-24.3
-
Face value
--
-
Shares outstanding
11,426,899
10 Years Aggregate
CFO
A$-106.10 Mln
EBITDA
A$-122.94 Mln
Net Profit
A$-119.65 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Kazia Therapeutics - ADR
| 86.2 | 1.7 | 2.1 | 59.0 | -62.5 | -65.6 | -39.6 |
|
BSE Sensex
| -9.6 | -2.0 | 3.1 | -4.7 | 5.4 | 6.0 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Kazia Therapeutics - ADR
| -84.4 | -59.5 | -28.4 | -92.8 | -2.5 | 99.1 | 78.6 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Kazia Therapeutics - ADR
|
12.8 | 155.2 | 0.0 | -20.7 | -3,568,435.1 | 226 | -- | 5.8 |
| 4.5 | 81.8 | 5.4 | -12.2 | -581.6 | -43.2 | -- | 2.1 | |
| 1.1 | 9.3 | 7.3 | -5.2 | -73.9 | -50.3 | -- | 1.0 |
Shareholding Pattern
View DetailsAbout Kazia Therapeutics - ADR
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the... phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia. Read more
-
CEO, MD & Director
Dr. John Edwin Friend II, M.D.
-
CEO, MD & Director
Dr. John Edwin Friend II, M.D.
-
Headquarters
Sydney, NSW
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Kazia Therapeutics - ADR
What is the current share price of Kazia Therapeutics Limited - ADR Today?
The share price of Kazia Therapeutics Limited - ADR is $12.83 (NASDAQ) as of 02-Sep-2026 14:37 EDT. Kazia Therapeutics Limited - ADR has given a return of -62.46% in the last 3 years.
What is the current PB & PE ratio of Kazia Therapeutics Limited - ADR?
Since, TTM earnings of Kazia Therapeutics Limited - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.26 |
-0.64 |
2024 |
0.00 |
-0.01 |
2023 |
-13.40 |
22.75 |
2022 |
-24.46 |
33.48 |
2021 |
-- |
-- |
What is the 52 Week High and Low of Kazia Therapeutics Limited - ADR?
The 52-week high and low of Kazia Therapeutics Limited - ADR are Rs 17.40 and Rs 4.86 as of 03-Sep-2026.
What is the market cap of Kazia Therapeutics Limited - ADR?
Kazia Therapeutics Limited - ADR has a market capitalisation of $ 155 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Kazia Therapeutics Limited - ADR?
Before investing in Kazia Therapeutics Limited - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.